Title: Extraordinary General Meeting in Nordic Nanovector
Reference is made to the announcement made on 18 June 2014 regarding the successful completion of the Company’s MUSD 41.6 (NOK 250 million) pre-IPO private placement.
The Board of Directors has resolved to call for an Extraordinary General Meeting to be held on 27 June 2014 at 15:00 (CET) in the Company’s offices at Kjelsåsveien 168 B, 4th floor, Oslo to approve the private placement, a MUSD 8.3 (NOK 50 million) subsequent share issue directed at those shareholders who do not participate in the private placement, increase in the authorization to the Board to issue new shares, changes to the articles of association and the election of a deputy Board member.
Attached is the notice of the Extraordinary General Meeting. The notice will be sent to the Nordic Nanovector shareholders today.
Jan A. Alfheim, CEO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 46 44 00 45
Fax: ( 47) 22 58 00 07
E-mail: jaa@nordicnanovector.no
Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07
E-mail: tkv@nordicnanovector.no
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
Tags:
